Literature DB >> 3335008

Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.

V Gandhi1, W Plunkett.   

Abstract

Previous studies have indicated that deoxycytidine kinase (dCK) is requisite and rate limiting in the phosphorylation of 1-beta-D-arabinofuranosylcytosine (ara-C) and 9-beta-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) on the pathway to their respective cytotoxic 5'-triphosphates. In K562 cells, the rate of triphosphate accumulation was maximal during incubation with 10 microM ara-C (35 microM/h) and 300 microM F-ara-A (102 microM/h). Under these conditions, accumulation of cellular ara-CTP plateaued at about 110 microM after 3 h, whereas in separate cultures, F-ara-ATP continued to accumulate at a linear rate to cellular concentrations greater than 500 microM after 5 h. Other laboratories have demonstrated that dCK activity in cell-free extracts was inhibited by ara-CTP. To determine whether ara-CTP exhibited the same activity in whole cells, K562 cells were preincubated with ara-C to accumulate 110 microM ara-CTP. After washing into medium containing F-ara-A, the rate of F-ara-ATP accumulation was significantly decreased (37 microM/h). However, cells loaded with F-ara-ATP exhibited an increased rate of ara-CTP accumulation (110 microM/h) that resulted in cellular ara-CTP concentrations in excess of 400 microM after 5 h. This stimulation was proportional to the cellular concentration of F-ara-ATP, achieving a maximum effect between 75 and 100 microM. Phosphorylation of ara-C by cell-free extracts supplemented with physiological levels of ribo- and deoxyribonucleoside 5'-triphosphates was stimulated by addition of F-ara-ATP. The decreased rate of accumulation of products of dCK in intact cells containing 110 microM ara-CTP suggests that this active triphosphate may limit its own synthesis and phosphorylation of other substrates. In contrast, stimulation of the accumulation of ara-CTP in cells containing F-ara-ATP suggests new possibilities for the design of combination chemotherapy regimens.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335008

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells.

Authors:  S Kewn; P G Hoggard; S D Sales; M A Johnson; D J Back
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

2.  LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.

Authors:  Roberto Rosato; Stefanie Hock; Paul Dent; Yun Dai; Steven Grant
Journal:  Leuk Res       Date:  2011-11-08       Impact factor: 3.156

3.  A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.

Authors:  Nicholas J Short; Hagop Kantarjian; Farhad Ravandi; Xuelin Huang; Lianchun Xiao; Guillermo Garcia-Manero; William Plunkett; Varsha Gandhi; Koji Sasaki; Naveen Pemmaraju; Naval G Daver; Gautam Borthakur; Nitin Jain; Marina Konopleva; Zeev Estrov; Tapan M Kadia; William G Wierda; Courtney D DiNardo; Mark Brandt; Susan M O'Brien; Jorge E Cortes; Elias Jabbour
Journal:  Leuk Lymphoma       Date:  2017-07-18

4.  Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.

Authors:  Rebecca B Klisovic; William Blum; Zhongfa Liu; Zhiliang Xie; Cheryl Kefauver; Lenguyen Huynh; James A Zwiebel; Steven M Devine; John C Byrd; Michael R Grever; Kenneth K Chan; Guido Marcucci
Journal:  Leuk Lymphoma       Date:  2013-11-01

Review 5.  Cellular and clinical pharmacology of fludarabine.

Authors:  Varsha Gandhi; William Plunkett
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 6.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 7.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

8.  Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.

Authors:  L V Ramilo-Torno; V I Avramis
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 9.  Acute myeloid leukaemia: optimising treatment in elderly patients.

Authors:  Graham H Jackson; Penelope R A Taylor
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

10.  Nelarabine in the treatment of refractory T-cell malignancies.

Authors:  Andrew M Roecker; Amy Stockert; David F Kisor
Journal:  Clin Med Insights Oncol       Date:  2010-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.